Categories AlphaGraphs, Earnings, Retail

Earnings: eBay Q2 revenue down 9%; profit beats estimates

E-commerce firm eBay Inc. (NASDAQ: EBAY) on Wednesday reported flat earnings for the second quarter of 2022 when the company’s revenues decreased. However, both the top-line and earnings beat analysts’ estimates.

eBay Q2 2022 earnings infographic

Adjusted earnings from continuing operations remained unchanged year-over-year at $0.99 per share, and topped expectations. On an unadjusted basis, it was a net loss from continuing operations of $536 million or $0.96 per share in the June quarter, compared to profit of $294 million or $0.43 per share in the same period of last year.

At $2.42 billion, second-quarter revenues were down 9% from the year-ago quarter. Market watchers were looking for a smaller topline number.

Check this space to read analysts/management’s comments on eBay’s Q2 earnings

eBay’s stock closed Wednesday’s regular trading higher and continued to gain during the extended session after the announcement.

Prior Performance

  • eBay Q4 2021 earnings infographic
  • eBay reports Q3 2021 earnings results
  • eBay Q2 2021 earnings infographic

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

WMT Earnings: All you need to know about Walmart’s Q2 2023 earnings results

Walmart Inc. (NYSE: WMT) reported second quarter 2023 earnings results today. Total revenue increased 8.4% year-over-year to $152.9 billion. Revenues grew 9.1% in constant currency. Consolidated net income attributable to

Rivian (RIVN) reaffirms production goals. Will it be a smooth ride?

The evolution of the electric vehicle industry accelerated in recent years even as innovations in battery technology and affordability brought EVs into the mainstream. Encouraged by the success of market

Pfizer (PFE): A look at the headwinds and tailwinds this pharma giant faces in the near term

Shares of Pfizer Inc. (NYSE: PFE) were down on Monday. The stock has dropped 15% year-to-date and there is a mixed sentiment surrounding the company’s growth prospects. Pfizer has benefited

Add Comment
Viewing Highlight